课题基金 / 基金详情

Estrogen Receptor Beta Pharmacology in the Prostate

Estrogen Receptor Beta Pharmacology in the Prostate
前列腺中雌激素受体 β 药理学
批准号:
7256950
负责人:
Daniel Edward Frigo
金额:
$5.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-01 至 2008-07-31

项目摘要

项目成果

Daniel Edward Frigo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Recently, ERbeta was demonstrated to inhibit androgen receptor signaling in the prostate and thus is likely to play a pivotal role in the regulation of prostate growth and differentiation. The objective of this proposal is to elucidate the role of ERbeta in androgen-responsive prostate cell models. To do this, ERbeta-interacting proteins will be identified using a T7 phage display system. Following the validation of these protein-protein interactions, we propose to determine the role of these proteins in modulating the physiological and pharmacological actions of ERbeta in androgen-mediated prostate growth mechanisms. To accomplish this, we propose the following specific aims: Aim 1. Identification of factors that interact with ERbeta-ligand complexes in androgen-responsive prostate model cell lines. Aim 2. Validation and characterization of ERbeta-interacting proteins in mammalian cells. Aim 3. Evaluation of the biological consequences of differential ERbeta-cofactor recruitment in androgen-responsive prostate cell lines.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Revisiting Antiangiogenic Therapy to Target Hormone-Sensitive Prostate Cancer Metabolism
Delineation of the Role of CAMKK2 in Bone-metastatic Prostate Cancer and its Therapeutic Implications
Delineation of the Role of CAMKK2 in Bone-metastatic Prostate Cancer and its Therapeutic Implications
海外基金